Azacitidine/Cedazuridine

阿扎胞苷/西达尿苷

Report date: 2022/12/07 17:52:48
NME

Base Information

Drug NameAzacitidine/Cedazuridine
Drug Alias NameCedazuridine+阿扎胞苷ASTX-030
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitorsCytidine deaminase inhibitors
TargetsDNA (cytosine-5)-methyltransferase 1Cytidine deaminase
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[11] 
CombinationsYes AzacitidineCedazuridine
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiho Pharmaceutical Co LtdTaiho Oncology Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A